Page last updated: 2024-10-17

bupropion and Body Weight

bupropion has been researched along with Body Weight in 36 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks."9.24Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017)
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs."9.17Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013)
" We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants."9.09Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001)
"Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking."8.81Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002)
" Sustained-release bupropion (bupropion SR) is the first non-nicotine pharmacological treatment approved for smoking cessation."8.81Clinical efficacy of bupropion in the management of smoking cessation. ( Jorenby, D, 2002)
", with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e."7.79Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. ( Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C, 2013)
"Bupropion treatment was rarely accompanied by reports of appetite change and had no statistically significant effect on caloric intake when compared to placebo."6.65Effects of bupropion on body weight. ( Cato, AE; Harto-Truax, N; Miller, LL; Sato, TL; Stern, WC, 1983)
"The relationship between seizure occurrence and use of bupropion was examined on the basis of manufacturer's reports."6.38Seizures and bupropion: a review. ( Davidson, J, 1989)
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks."5.24Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017)
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs."5.17Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013)
"In people with elevated blood pressure, orlistat, phentermine/topiramate and naltrexone/bupropion reduced body weight; the magnitude of the effect was greatest with phentermine/topiramate."5.12Long-term effects of weight-reducing drugs in people with hypertension. ( Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S, 2021)
" In this study of a 12-week randomized trial of nicotine inhaler, bupropion or both for smoking cessation, 50% of the 1012 female smokers and 26% of the 680 male smokers, at study entry, were weight concerned."5.12The prevalence of weight concerns in a smoking abstinence clinical trial. ( Bernath, A; Clark, MM; Croghan, GA; Croghan, IT; Dakhil, SR; Ebbert, LP; Garneau, S; Hurt, RD; Loprinzi, CL; Morton, RF; Novotny, P; Patten, CA; Rowland, KM; Sloan, JA; Stella, PJ; Thomas, SP; Tschetter, LK; Wender, DB; Wos, EJ, 2006)
" We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants."5.09Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001)
"Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking."4.81Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002)
" Sustained-release bupropion (bupropion SR) is the first non-nicotine pharmacological treatment approved for smoking cessation."4.81Clinical efficacy of bupropion in the management of smoking cessation. ( Jorenby, D, 2002)
" This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents."4.02Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. ( Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P, 2021)
", with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e."3.79Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. ( Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C, 2013)
"Bupropion treatment was rarely accompanied by reports of appetite change and had no statistically significant effect on caloric intake when compared to placebo."2.65Effects of bupropion on body weight. ( Cato, AE; Harto-Truax, N; Miller, LL; Sato, TL; Stern, WC, 1983)
"Treating tobacco dependence is effective in patients with SMI."2.46Smoking cessation in severe mental illness: what works? ( Banham, L; Gilbody, S, 2010)
"Bupropion is presumed to be a dopamine-norepinephrine reuptake inhibitor and is an effective antidepressant."2.44Bupropion: a review of its use in the management of major depressive disorder. ( Curran, MP; Dhillon, S; Yang, LP, 2008)
"The relationship between seizure occurrence and use of bupropion was examined on the basis of manufacturer's reports."2.38Seizures and bupropion: a review. ( Davidson, J, 1989)
"Corticosterone treatment resulted in marked adrenal atrophy and flattening of the glucocorticoid rhythm as measured by repeated blood sampling."1.35Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder. ( Fairchild, G; Gartside, SE; Ingram, CD; McQuade, R; Minton, GO; Young, AH, 2009)
"Because obesity can affect catecholaminergic signaling, we determined the effects of i."1.34Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. ( Billes, SK; Cowley, MA, 2007)
"Rehabilitation of COPD-patients is an important part of the therapeutic management."1.33[COPD-rehabilitation]. ( Lichtenschopf, A; Zwick, H, 2005)
"Bipolar affective disorders can be successfully treated with long-term use of the mood stabilizer lithium."1.33Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat. ( Ferrie, L; McQuade, R; Young, AH, 2005)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19909 (25.00)18.7374
1990's3 (8.33)18.2507
2000's14 (38.89)29.6817
2010's6 (16.67)24.3611
2020's4 (11.11)2.80

Authors

AuthorsStudies
Roberto da Silva, G1
Carneiro, MG1
Barbosa, MP1
Costa, JA1
de Souza, IA1
Dos Santos Oliveira, L1
de Vasconcelos, DAA1
do Nascimento, E1
Matos, RJB1
Lopes de Souza, S1
de Freitas, MFL1
Grilo, CM1
Lydecker, JA1
Morgan, PT1
Gueorguieva, R1
Siebenhofer, A1
Winterholer, S1
Jeitler, K1
Horvath, K1
Berghold, A1
Krenn, C1
Semlitsch, T1
Wharton, S1
Yin, P1
Burrows, M1
Gould, E1
Blavignac, J1
Christensen, RAG1
Kamran, E1
Camacho, F1
Barakat, M1
Hollander, P1
Gupta, AK1
Plodkowski, R1
Greenway, F1
Bays, H1
Burns, C1
Klassen, P1
Fujioka, K2
Halseth, A1
Shan, K1
Walsh, B1
Gilder, K1
Kapoor, S1
Minton, GO1
Young, AH2
McQuade, R2
Fairchild, G1
Ingram, CD1
Gartside, SE1
Banham, L1
Gilbody, S1
Bray, GA1
Ryan, DH1
Levine, MD1
Cheng, Y1
Kalarchian, MA1
Perkins, KA1
Marcus, MD1
Clapper, JR1
Athanacio, J1
Wittmer, C1
Griffin, PS1
D'Souza, L1
Parkes, DG1
Roth, JD1
Tonstad, S1
Jorenby, D1
Carter, GT1
Yudkowsky, MP1
Han, JJ1
McCrory, MA1
Zwick, H1
Lichtenschopf, A1
Ferrie, L1
Clark, MM2
Hays, JT1
Vickers, KS1
Patten, CA2
Croghan, IT2
Berg, E1
Wadewitz, S1
Schwartz, S1
Decker, PA1
Offord, KP1
Squires, RW1
Hurt, RD2
Novotny, P1
Sloan, JA1
Dakhil, SR1
Croghan, GA1
Wos, EJ1
Rowland, KM1
Bernath, A1
Morton, RF1
Thomas, SP1
Tschetter, LK1
Garneau, S1
Stella, PJ1
Ebbert, LP1
Wender, DB1
Loprinzi, CL1
Modell, JG1
Rosenthal, NE1
Harriett, AE1
Krishen, A1
Asgharian, A1
Foster, VJ1
Metz, A1
Rockett, CB1
Wightman, DS1
Billes, SK1
Cowley, MA1
Hsieh, YS1
Yang, SF1
Chiou, HL1
Kuo, DY1
Dhillon, S1
Yang, LP1
Curran, MP1
Davidson, J2
Miller, R1
Van Wyck Fleet, J1
Strickland, R1
Manberg, P1
Allen, S1
Parrott, R1
Shopsin, B1
Gardner, EA2
Harto-Truax, N1
Stern, WC2
Miller, LL2
Sato, TL1
Cato, AE1
Feighner, JP2
Meredith, CH1
Hendrickson, G2
Callaghan, RS1
Chengappa, KN1
Kambhampati, RK1
Perkins, K1
Nigam, R1
Anderson, T1
Brar, JS1
Vemulapalli, HK1
Atzert, R1
Key, P1
Kang, JS1
Levine, J1
Johnston, JA1
Batey, SR1
Khayrallah, MA1
Ascher, JA1
Lineberry, CG1
Yutrzenka, GJ1
Patrick, GA1
Rosenberger, W1
Wright, G1
Galloway, L1
Kim, J1
Dalton, M1
Miller, L2
Stern, W2
Feighner, J1
Nobrega, JN1
Coscina, DV1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo[NCT02317744]22 participants (Actual)Interventional2014-12-31Completed
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus[NCT00474630]Phase 3505 participants (Actual)Interventional2007-05-31Completed
A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)[NCT01764386]Phase 3242 participants (Actual)Interventional2013-02-28Completed
Effectiveness of a Smoking Cessation Quit Line for Mental Health Patients: Pragmatic Clinical Trial[NCT03230955]300 participants (Actual)Interventional2017-05-02Completed
Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder[NCT00502320]Phase 450 participants (Actual)Interventional2006-09-30Completed
Acute Efficacy of Bupropion, Sertraline, and Venlafaxine as Adjuvant Treatment to Mood Stabilizers in Bipolar Depression: A Randomized, Double-Blind, Comparative Study[NCT00001483]Phase 275 participants Interventional1995-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Binge Eating Frequency (Continuous)

Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)

Interventionbinge eating days (out of 28) (Mean)
Naltrexone/ Bupropion Combination5.4
Pill Placebo2.9

Binge Eating Frequency (Continuous)

Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: Post-treatment (at 3 months)

Interventionbinge eating days (out of 28) (Mean)
Naltrexone/ Bupropion Combination4.4
Pill Placebo3.0

Body Mass Index (BMI)

BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)

Interventionkg/m^2 (Mean)
Naltrexone/ Bupropion Combination35.9
Pill Placebo40.3

Body Mass Index (BMI)

BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: Post-treatment (at 3 months)

Interventionkg/m^2 (Mean)
Naltrexone/ Bupropion Combination34.5
Pill Placebo39.7

Body Weight- Proportion of Subjects With ≥10% Decrease

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3218.49
Placebo5.66

Change in Diastolic Blood Pressure

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB32-1.06
Placebo-1.47

Change in Fasting Blood Glucose Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB32-11.87
Placebo-4.02

Change in Fasting HDL Cholesterol Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB323.03
Placebo-0.29

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-13.48
Placebo-10.35

Change in Fasting LDL Cholesterol Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB32-1.44
Placebo-0.01

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-11.20
Placebo-0.80

Change in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-1.48
Placebo-1.52

Change in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-1.97
Placebo-2.40

Change in HbA1c Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent (Least Squares Mean)
NB32-0.63
Placebo-0.14

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-20.91
Placebo-13.29

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-20.56
Placebo-14.67

Change in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB320.01
Placebo-1.60

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB329.27
Placebo7.90

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-11.89
Placebo-6.91

Change in Systolic Blood Pressure

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB320.03
Placebo-1.12

Change in Waist Circumference

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventioncm (Least Squares Mean)
NB32-4.97
Placebo-2.89

Co-primary: Body Weight- Mean Percent Change

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-5.03
Placebo-1.75

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3244.53
Placebo18.87

HbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3220.72
Placebo10.22

HbA1c- Proportion of Subjects With HbA1c <7% at Endpoint

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3244.14
Placebo26.28

Percent of Subjects Discontinuing Due to Poor Glycemic Control

Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control. (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB320
Placebo1.89

Percent of Subjects Requiring Rescue Medications for Diabetes

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3222.26
Placebo35.22

Percent of Subjects With Dose Increase in Oral Antidiabetes Medications

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB323.02
Placebo1.26

Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB321.89
Placebo1.26

Absolute Change in Body Weight From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionkg (Least Squares Mean)
NB + CLI-9.7
Usual Care-1.0

Change Fasting Insulin From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

InterventionuIU/mL (Least Squares Mean)
NB + CLI-7.5
Usual Care-3.4

Change in Diastolic Blood Pressure From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmm Hg (Least Squares Mean)
NB + CLI-1.7
Usual Care-1.3

Change in Fasting High-density Lipoprotein Cholesterol From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI4.1
Usual Care0.1

Change in Fasting Low-density Lipoprotein Cholesterol From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI-2.0
Usual Care-1.9

Change in Fasting Plasma Glucose From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI-2.9
Usual Care1.6

Change in Fasting Triglycerides From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI-13.6
Usual Care2.8

Change in Heart Rate From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionbpm (Least Squares Mean)
NB + CLI1.7
Usual Care-0.3

Change in Homeostasis Model Assessment-insulin Resistance (HOMA-IR) From Baseline to Week 26

HOMA-IR is an insulin sensitivity index that is calculated as HOMA-IR = (Glucose * Insulin) / 405, where glucose is in mass units (mg/dL) and insulin is in µIU/mL. Higher values indicate lower insulin sensitivity. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI-2.0
Usual Care-0.8

Change in Patient-reported Arizona Sexual Experiences Scale (ASEX) Total Scores From Baseline to Week 26

Arizona Sexual Experiences (ASEX) scale is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI-2.2
Usual Care-0.1

Change in Patient-reported Binge Eating Scale (BES) Total Scores From Baseline to Week 26

The BES is a 16-item questionnaire that identifies different levels of binge-eating severity, with total scores ranging between 0-46. BES scores were categorized as follows: None = Scores ≤17 indicated no significant binge eating, Moderate = scores from 18 to 26 (inclusive), Severe = scores ≥27 indicated severe levels of binge eating. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI-6.8
Usual Care1.1

Change in Patient-reported Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) Total Score From Baseline to Week 26

Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) is a self-reported assessment of perceived effect of weight on quality of life. It consists of 31 items organized in 5 domains (physical function, self-esteem, sexual life, public distress and work). IWQOL-Lite total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI16.4
Usual Care-1.0

Change in Systolic Blood Pressure From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmm Hg (Least Squares Mean)
NB + CLI-4.8
Usual Care-2.8

Change in Waist Circumference From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventioncm (Least Squares Mean)
NB + CLI-6.96
Usual Care-1.64

Percent Change in Body Weight From Baseline (Day 1) to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercent change in body weight (Least Squares Mean)
NB + CLI-9.46
Usual Care-0.94

Percentage of Subjects Achieving a Loss of at Least 10% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercentage of participants (Number)
NB + CLI42.3
Usual Care3.7

Percentage of Subjects Achieving a Loss of at Least 15% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercentage of participants (Number)
NB + CLI12.7
Usual Care0.0

Percentage of Subjects Achieving a Loss of at Least 5% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercentage of participants (Number)
NB + CLI84.5
Usual Care12.2

Depressive Symptoms at Baseline and Measured Monthly, as Measured by the Structured Interview Guide for the Hamilton Depression Rating - Seasonal Affective Disorder (SIGH-SAD)

Clinician-rated measure of mood; evaluates classical 21 Hamilton Depression items, and 8-item subscale measuring atypical depression symptoms which commonly occur during SAD episodes. Score ranges from 0-89, higher scores indicate higher levels of depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)

,
Interventionscores on a scale (Mean)
BaselineMonth 1Month 2Month 3Month 4
Placebo19.9915.9719.4720.6523.68
Ramelteon22.6816.1614.8111.699.15

Depressive Symptoms at Baseline and Measured Monthly, as Measured by the Zung Depression Scale (ZDS)

Self-rated scale to measure severity of depressive symptoms. Score ranges from 25-100, higher scores reflect more depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)

,
Interventionscores on a scale (Mean)
BaselineMonth 1Month 2Month 3Month 4
Placebo58.6356.4058.5958.6261.65
Ramelteon63.0654.3553.5149.2646.14

Sleep Satisfaction at Baseline and Measured Monthly, as Measured by the Pittsburgh Sleep Quality Index (PSQI)

Self-rated scale to measure quality of sleep via questions regarding sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction. Score ranges from 0-21, higher scores represent more significant sleep disturbance. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)

,
Interventionscores on a scale (Mean)
BaselineMonth 1Month 2Month 3Month 4
Placebo11.458.678.629.889.61
Ramelteon11.569.527.578.077.05

Reviews

6 reviews available for bupropion and Body Weight

ArticleYear
Long-term effects of weight-reducing drugs in people with hypertension.
    The Cochrane database of systematic reviews, 2021, 01-17, Volume: 1

    Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet

2021
Smoking cessation in severe mental illness: what works?
    Addiction (Abingdon, England), 2010, Volume: 105, Issue:7

    Topics: Adult; Behavior Therapy; Body Weight; Bupropion; Dopamine Uptake Inhibitors; Female; Healthcare Disp

2010
Use of sustained-release bupropion in specific patient populations for smoking cessation.
    Drugs, 2002, Volume: 62 Suppl 2

    Topics: Alcoholism; Body Weight; Bupropion; Delayed-Action Preparations; Depression; Dopamine Uptake Inhibit

2002
Clinical efficacy of bupropion in the management of smoking cessation.
    Drugs, 2002, Volume: 62 Suppl 2

    Topics: Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Drug Administration

2002
Bupropion: a review of its use in the management of major depressive disorder.
    Drugs, 2008, Volume: 68, Issue:5

    Topics: Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Citalopram; Delayed-Action Prepara

2008
Seizures and bupropion: a review.
    The Journal of clinical psychiatry, 1989, Volume: 50, Issue:7

    Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents; Body Weight; Bupropion; Cohort Studies;

1989

Trials

15 trials available for bupropion and Body Weight

ArticleYear
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
    Clinical therapeutics, 2021, Volume: 43, Issue:1

    Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Body Weight; Bupropion; Double-Blind Method; Drug

2021
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
    Diabetes care, 2013, Volume: 36, Issue:12

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupro

2013
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
    Obesity (Silver Spring, Md.), 2017, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors;

2017
Dietary intake after smoking cessation among weight-concerned women smokers.
    Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2012, Volume: 26, Issue:4

    Topics: Body Weight; Bupropion; Diet; Eating; Female; Humans; Smoking; Smoking Cessation; Weight Gain

2012
Body image treatment for weight concerned smokers: a pilot study.
    Addictive behaviors, 2005, Volume: 30, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Body Image; Body Weight; Bupropion; Cognit

2005
The prevalence of weight concerns in a smoking abstinence clinical trial.
    Addictive behaviors, 2006, Volume: 31, Issue:7

    Topics: Adult; Antidepressive Agents, Second-Generation; Body Image; Body Weight; Bupropion; Female; Humans;

2006
Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.
    Biological psychiatry, 2005, Oct-15, Volume: 58, Issue:8

    Topics: Adult; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Double-Blind Method; Drug A

2005
A double-blind comparison of bupropion and amitriptyline in depressed inpatients.
    The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Pt 2

    Topics: Adult; Amitriptyline; Antidepressive Agents; Appetite; Body Weight; Bupropion; Clinical Trials as To

1983
Bupropion: a new clinical profile in the psychobiology of depression.
    The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Pt 2

    Topics: Antidepressive Agents; Bipolar Disorder; Body Weight; Bupropion; Clinical Trials as Topic; Depressiv

1983
Effects of bupropion on body weight.
    The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Pt 2

    Topics: Amitriptyline; Antidepressive Agents; Appetite; Body Weight; Bupropion; Clinical Trials as Topic; Do

1983
A double-blind study of bupropion and placebo in depression.
    The American journal of psychiatry, 1984, Volume: 141, Issue:4

    Topics: Adult; Aged; Antidepressive Agents; Body Weight; Bupropion; Clinical Trials as Topic; Depressive Dis

1984
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:7

    Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Bupropion; Comorbidity; Delayed-Action Prepar

2001
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    The Journal of clinical psychiatry, 1991, Volume: 52, Issue:8

    Topics: Adult; Ambulatory Care; Antidepressive Agents; Body Weight; Bupropion; Depressive Disorder; Dose-Res

1991
Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects.
    The Journal of clinical psychiatry, 1985, Volume: 46, Issue:1

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Body Weight; Bupropion; Chroni

1985
Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder.
    Journal of clinical psychopharmacology, 1986, Volume: 6, Issue:1

    Topics: Adult; Aged; Antidepressive Agents; Body Weight; Bupropion; Clinical Trials as Topic; Depressive Dis

1986

Other Studies

15 other studies available for bupropion and Body Weight

ArticleYear
Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats.
    The Journal of endocrinology, 2022, 04-13, Volume: 253, Issue:3

    Topics: Animals; Body Weight; Bupropion; Diet, High-Fat; Eating; Gene Expression; Naltrexone; Obesity; Rats;

2022
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
    International journal of obesity (2005), 2021, Volume: 45, Issue:8

    Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypogl

2021
Strategies to control antipsychotic-induced weight gain.
    Psychoneuroendocrinology, 2008, Volume: 33, Issue:8

    Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; F

2008
Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:10

    Topics: Adrenal Glands; Animals; Anti-Inflammatory Agents; Body Weight; Bupropion; Circadian Rhythm; Cortico

2009
Drug treatment of obesity.
    The Psychiatric clinics of North America, 2011, Volume: 34, Issue:4

    Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupro

2011
Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.
    European journal of pharmacology, 2013, Jan-05, Volume: 698, Issue:1-3

    Topics: Animals; Appetite Depressants; Body Composition; Body Weight; Bupropion; Diet; Drug Interactions; Ea

2013
Topiramate for weight reduction in Duchenne muscular dystrophy.
    Muscle & nerve, 2005, Volume: 31, Issue:6

    Topics: Adolescent; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Appetite; Body Weight; Bu

2005
[COPD-rehabilitation].
    Wiener medizinische Wochenschrift (1946), 2005, Volume: 155, Issue:5-6

    Topics: Acupuncture Therapy; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Antidepres

2005
Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat.
    Journal of psychopharmacology (Oxford, England), 2005, Volume: 19, Issue:3

    Topics: Animals; Body Weight; Bupropion; Chromatography, High Pressure Liquid; Dopamine; Dopamine Plasma Mem

2005
Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:4

    Topics: Animals; Behavior, Animal; Body Weight; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drug

2007
Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression.
    Behavioral neuroscience, 2007, Volume: 121, Issue:5

    Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Bupropion; Catecholamines; Catheterization;

2007
Long-term preventive care in depression: the use of bupropion in patients intolerant of other antidepressants.
    The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Pt 2

    Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Tricyclic; Body Weight;

1983
Appetite and weight in children treated for ADHD.
    Journal of the American Academy of Child and Adolescent Psychiatry, 1999, Volume: 38, Issue:7

    Topics: Appetite Regulation; Attention Deficit Disorder with Hyperactivity; Body Weight; Bupropion; Central

1999
Substitution of psychoactive drugs in pentobarbital-dependent rats.
    Drug and alcohol dependence, 1990, Volume: 26, Issue:1

    Topics: Animals; Antidepressive Agents; Arousal; Body Weight; Brain; Bromazepam; Bupropion; Diazepam; Dose-R

1990
Dopamine-norepinephrine interactions in the development of hyperphagia and obesity following medial hypothalamic lesions.
    Pharmacology, biochemistry, and behavior, 1986, Volume: 25, Issue:2

    Topics: Animals; Body Weight; Brain Mapping; Bupropion; Dopamine; Feeding Behavior; Female; Hydroxydopamines

1986